أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ethinylestradiol, quantity: 0.02 mg; drospirenone, quantity: 3 mg - tablet - excipient ingredients: polacrilin potassium; magnesium stearate; lactose monohydrate - drospirenone/ethinyloestradiol-alphapharm 3/20 is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg/ethinyloestradiol 20 ?g tablets for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg/ethinyloestradiol 20 ?g tablets has not been evaluated for treatment of pms (premenstrual syndrome) (see clinical trials).

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone,ethinylestradiol -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 0.02 mg - tablet - excipient ingredients: polacrilin potassium; lactose monohydrate; magnesium stearate - zaida 3/20 is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg/ethinyloestradiol 20 ?g tablets for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg/ethinyloestradiol 20 ?g tablets has not been evaluated for treatment of pms (premenstrual syndrome) (see clinical trials).

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; povidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 0.03 mg - tablet - excipient ingredients: polacrilin potassium; lactose monohydrate; magnesium stearate - zaida 3/30 is indicated for use as an oral contraceptive.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - drospirenone,ethinylestradiol -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - drospirenone,ethinylestradiol -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: lactose; magnesium stearate; povidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose; povidone; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 30 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; dl-alpha-tocopherol; maize starch; pregelatinised maize starch; brilliant blue fcf; magnesium stearate - indicated for use as an oral contraceptive